biostudies-literatureUnknownHuang YNIAID NIH HHSSynergy of antimicrobial combinations was tested against contemporary <i>Mycobacteroides</i> abscessus isolates using 2-D and 3-D checkerboard assays. Triple combinations of omadacycline-azithromycin-clofazimine, tigecycline-azithromycin-clofazimine, omadacycline-azithromycin-linezolid and omadacycline-azithromycin-contezolid demonstrated synergy (FIC ≤ 0.5) against 33%, 31%, 62%, and 66% of isolates, respectively. Notably, in all triple combinations, macrolide resistant <i>M. abscessus</i> subsp. <i>abscessus</i> and <i>M. abscessus</i> subsp. <i>bolletii</i> isolates were fully sensitized to azithromycin at the FIC index, as were isolates with elevated clofazimine MICs.bioRxiv : the preprint server for biology2025.02.13.638181https://www.ebi.ac.uk/biostudies/studies/S-EPMC11844545biostudies-literatureTriple antimicrobial combinations with potent synergistic activity against <i>M. abscessus</i>.PMC11844545T32 AI007061Huang YBode-Sojobi IChiaraviglio LKirby JEfalseTriple antimicrobial combinations with potent synergistic activity against <i>M. abscessus</i>.Synergy of antimicrobial combinations was tested against contemporary <i>Mycobacteroides</i> abscessus isolates using 2-D and 3-D checkerboard assays. Triple combinations of omadacycline-azithromycin-clofazimine, tigecycline-azithromycin-clofazimine, omadacycline-azithromycin-linezolid and omadacycline-azithromycin-contezolid demonstrated synergy (FIC ≤ 0.5) against 33%, 31%, 62%, and 66% of isolates, respectively. Notably, in all triple combinations, macrolide resistant <i>M. abscessus</i> subsp. <i>abscessus</i> and <i>M. abscessus</i> subsp. <i>bolletii</i> isolates were fully sensitized to azithromycin at the FIC index, as were isolates with elevated clofazimine MICs.2025-01-01T00:00:00Z2025 Feb2026-04-08T19:02:45.137Z2025-06-26T03:06:03.665ZS-EPMC118445453999035110.1101/2025.02.13.638181